I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited
SHANGHAI and GAITHERSBURG, Md., Dec. 7, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Board of Directors of the Company (the "Board") approved a motion to pursue the listing of the Company's ordinary shares...
VR Digital Therapeutics for depression developed in consultation with specialists from Boston, MA, U.S.A., introducing innovative clinical tool at CES2022
TOKYO, Dec. 7, 2021 /PRNewswire/ -- Jolly Good Inc. ("Jolly Good"), a leading Japanese VR company which develops and provides medical VR and VR digital therapeutics, is expanding overseas and has developed an English version of its VR digital therapeutic tool that facilitates the treatment of depression ("VRDTx"). Jolly Good has invited Dr. Katharine "Kim" Larsson and Dr. Amaro...
SyMap Medical Ltd. Closes Largest Financing Round in Renal Denervation Field
SUZHOU, China, Dec. 7, 2021 /PRNewswire/ -- SyMap Medical (SyMap) announced its latest financing round of nearly $100 million led by Primavera Capital and VMS Group, with the participation of existing investors Simiao Equity Investment and Sequoia Capital China. CEC Capital served as the exclusive financial advisor for this transaction. ...
Leading Organizations Awarded Excellence in Best Practices by Frost & Sullivan for Exemplary Achievements
17 companies are set to be recognized at the 3rd Frost & Sullivan 2021 Virtual Awards Ceremony, which will be broadcasted live on YouTube at 6:00 p.m. (GMT +8), 14 December 2021. SINGAPORE, Dec. 7, 2021 /PRNewswire/ -- Frost & Sullivan Best Practices Awards is honoring 17 top companies at the 19th annual Best Practices Awards on 14 December...
Sino Biological newly launched a panel of research reagents for SARS-CoV-2 Omicron variant
BEIJING, China, Dec. 7, 2021 /PRNewswire/ -- Sino Biological, Inc. (http://www.sinobiological.com; SHE: 301047) announced today that it has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-COV-2 virus, which quickly raised concerns around the world because of the high number of mutations it carries, especially the 30-plus mutations on the Spike...
Overland Pharmaceuticals Partners with ArisGlobal to Accelerate Safety Capabilities
Premier pharmaceutical company adopts LifeSphere Multivigilance to centralize pharmacovigilance activities MIAMI, Dec. 7, 2021 /PRNewswire/ -- ArisGlobal, the leading provider of life sciences software that automates core drug development with its end-to-end drug development technology platform LifeSphere® today announced its partnership with Overland Pharmaceuticals. Overland, a premier biopharmaceutical company bringing innovative medicines...
Clarivate Report Finds Telehealth Can Close Gaps in Care and Ease Disparities
New report investigates how telehealth can reduce healthcare disparities in the treatment of Black Americans LONDON, Dec. 7, 2021 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of a new report, entitled Realizing telehealth's potential to reduce healthcare disparities: How healthcare stakeholders can...
Samsung Biologics adds to global ISO certifications with Quality Management System
Samsung Biologics earns ISO9001 for Quality Management System, proving its capabilities to ensure high-quality service offerings throughout a product life-cycle The company is fully certified with the recognition across all of its CDO, CMO and all other core business units in Plant 1,2, and 3 INCHEON, South Korea, Dec. 7, 2021 /PRNewswire/ -- Samsung Biologics (KRX:...
QUOMI Launches An Innovative, Premium, Digital, Community Network For Healthcare Professionals (HCP)
DORTMUND, Germany, Dec. 7, 2021 /PRNewswire/ -- QUOMI as a premium, digital, healthcare community aims at bringing a new order and possibilities for all levels of HCP by disrupting old structures and setting new standards. We have created a platform that is extremely user friendly, offering authentic content shared by verified members while ensuring...
Akeso Announces Launch of U.S. Investigator-Initiated Study of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody)
HONG KONG, Dec. 7, 2021 /PRNewswire/ -- Today, Akeso, Inc. (9926.HK) announced that the company will support an investigator-initiated study (IIS) to evaluate the efficacy and safety of Akeso's novel, first-in-class anti-PD-1/CTLA-4 bispecific antibody, cadonilimab, for the treatment of neuroendocrine cervical carcinoma in the United States. Following a review of the efficacy data from the Akeso-sponsored Phase 2...
